Antimyostatin treatment in health and disease

Antimyostatin treatment in health and disease: The story of great expectations and limited success

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Antimyostatin treatment in health and disease : The story of great expectations and limited success. / Nielsen, Tue L.; Vissing, John; Krag, Thomas O.

I: Cells, Bind 10, Nr. 3, 533, 2021.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Nielsen, TL, Vissing, J & Krag, TO 2021, 'Antimyostatin treatment in health and disease: The story of great expectations and limited success', Cells, bind 10, nr. 3, 533. https://doi.org/10.3390/cells10030533

APA

Nielsen, T. L., Vissing, J., & Krag, T. O. (2021). Antimyostatin treatment in health and disease: The story of great expectations and limited success. Cells, 10(3), [533]. https://doi.org/10.3390/cells10030533

Vancouver

Nielsen TL, Vissing J, Krag TO. Antimyostatin treatment in health and disease: The story of great expectations and limited success. Cells. 2021;10(3). 533. https://doi.org/10.3390/cells10030533

Author

Nielsen, Tue L. ; Vissing, John ; Krag, Thomas O. / Antimyostatin treatment in health and disease : The story of great expectations and limited success. I: Cells. 2021 ; Bind 10, Nr. 3.

Bibtex

@article{f4be1f0531824229b74d61809b596ee3,

title = "Antimyostatin treatment in health and disease: The story of great expectations and limited success",

abstract = "In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical studies have shown potential for increasing muscular mass and ameliorating the pathological features of dystrophic muscle by the inhibition of myostatin in various ways. However, hardly any clinical trials have proven to translate the promising results from the animal models into patient popula-tions. We present the background for myostatin regulation, clinical and preclinical results and dis-cuss why translation from animal models to patients is difficult. Based on this, we put the clinical relevance of future antimyostatin treatment into perspective.",

keywords = "ActRIIB, Muscular dystrophy, Muscular regeneration, Myostatin, TGF-β",

author = "Nielsen, {Tue L.} and John Vissing and Krag, {Thomas O.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

doi = "10.3390/cells10030533",

language = "English",

volume = "10",

journal = "Cells",

issn = "2073-4409",

publisher = "MDPI AG",

number = "3",

}

RIS

TY - JOUR

T1 - Antimyostatin treatment in health and disease

T2 - The story of great expectations and limited success

AU - Nielsen, Tue L.

AU - Vissing, John

AU - Krag, Thomas O.

PY - 2021

Y1 - 2021

N2 - In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical studies have shown potential for increasing muscular mass and ameliorating the pathological features of dystrophic muscle by the inhibition of myostatin in various ways. However, hardly any clinical trials have proven to translate the promising results from the animal models into patient popula-tions. We present the background for myostatin regulation, clinical and preclinical results and dis-cuss why translation from animal models to patients is difficult. Based on this, we put the clinical relevance of future antimyostatin treatment into perspective.

AB - In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical studies have shown potential for increasing muscular mass and ameliorating the pathological features of dystrophic muscle by the inhibition of myostatin in various ways. However, hardly any clinical trials have proven to translate the promising results from the animal models into patient popula-tions. We present the background for myostatin regulation, clinical and preclinical results and dis-cuss why translation from animal models to patients is difficult. Based on this, we put the clinical relevance of future antimyostatin treatment into perspective.

KW - ActRIIB

KW - Muscular dystrophy

KW - Muscular regeneration

KW - Myostatin

KW - TGF-β

U2 - 10.3390/cells10030533

DO - 10.3390/cells10030533

M3 - Review

C2 - 33802348

AN - SCOPUS:85103863032

VL - 10

JO - Cells

JF - Cells

SN - 2073-4409

IS - 3

M1 - 533

ER -

ID: 303674000